Abstract: Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing compound. The amount of propylene glycol may be varied to adjust the initial flux of the NSAID through the skin, especially for ibuprofen, naproxen, and ketorolac.

Abstract: A nail lacquer for the treatment or prevention of fungal infections, such as, onychomycosis, includes fungicidally effective amount of ciclopirox, econazole, or other antifungal agent in a compatible film-forming lacquer vehicle which includes a water-insoluble film-forming polymer; pentadecalactone, or similar cyclic lactone compound or derivative thereof, and volatile solvent. The pentadecalactone functions as a plasticizer for the film-forming polymer and as a penetration enhancer for the antifungal agent. The composition, when applied to the nails provides a hard, clear, water-resistant film containing the antifungal agent. The compositions are used for the treatment of onychomycosis.

Abstract: A nail lacquer for the treatment or prevention of fungal infections, such as, onychomycosis, includes fungicidally effective amount of ciclopirox, econazole, or other antifungal agent in a compatible film-forming lacquer vehicle which includes a water-insoluble film-forming polymer; pentadecalactone, or similar cyclic lactone compound or derivative thereof, and volatile solvent. The pentadecalactone functions as a plasticizer for the film-forming polymer and as a penetration enhancer for the antifungal agent. The composition, when applied to the nails provides a hard, clear, water-resistant film containing the antifungal agent. The compositions are used for the treatment of onychomycosis.

Abstract: A nail lacquer effective for the treatment or prevention of fungal infections, such as, onychomycosis, includes fungicidally effective amount of ciclopirox, econazole, or other antifungal agent in a clear, stable, film-forming lacquer vehicle which includes a water-insoluble film-forming polymer; 2-n-nonyl-1,3-dioxolane or similar penetration enhancer; and volatile solvent. A plasticizer for the film-forming polymer which is also compatible with the other components may be included although the preferred penetration enhancers may also function as plasticizer. The composition, when applied to the nails provides a hard, clear, water-resistant film containing the antifungal agent. The film is resistant to multiple washings and is effective in the treatment of onychomycosis.

Abstract: Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing compound. The amount of propylene glycol may be varied to adjust the initial flux of the NSAID through the skin, especially for ibuprofen, naproxen, and ketorolac.

Abstract: Topical alcoholic or aqueous alcoholic gels containing testosterone, progesterone, estradiol or other hormones have enhanced penetration through skin by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing compound.

Abstract: A composition for the topical transdermal administration to the penis is based on prostaglandin E.sub.1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E.sub.1 active ingredient through the skin. Phentolamine or prazosin may be used in combination with prostaglandin E.sub.1.

Abstract: A mixture of lipophilic and amphiphilic/hydrophilic film-forming polymers of the formula (I): R(CO).sub.m O--(CH.sub.2 CHR.sup.1 O).sub.n --?OCNH--Z--NHCO.sub.2 (CH.sub.2 CHR.sup.2 O).sub.n' !.sub.p --OCNH--Z--NHCO.sub.2 --(CH.sub.2 CHR.sup.1 O).sub.n --(CO).sub.m R, wherein R represents (i) an alkyl, alkenyl or alkaryl hydrocarbyl group of from 1 to 3 carbon atoms or (ii) a polypropylene oxide group (PPO); R.sup.1 and R.sup.2, each, independently, represent a hydrogen atom, or a methyl or ethyl group; Z represents a divalent linking hydrocarbyl group; m is 0 or 1; n and n', are each, independently, a positive number; and p is >0, preferably p is 0 or 1, provide a skin substantive, occlusive moisture barrier covering for skin or hair. The compositions have a moisturizing effect by reducing transepidermal water loss.

Abstract: A mixture of lipophilic and amphiphilic/hydrophilic film-forming polymers of the formula (I)R--(CO).sub.m Y.sup.1 --(CH.sub.2 CHR.sup.1 O).sub.n --?CONH--Z--NHCO(OCH.sub.2 CHR.sup.2).sub.n' --Y.sup.2 --(CH.sub.2 CHR.sup.2 O).sub.n" !.sub.p --CONH--Z--NHCO--(OCH.sub.2 CHR.sup.1).sub.n --Y.sup.1 (CO).sub.m R (I)where R represents (i) an alkyl, alkenyl or alkaryl group of from 1 to 30 carbon atoms or (ii) a polypropylene oxide group or polybutylene oxide group; R.sup.1 and R.sup.2, each, independently, represent a hydrogen atom, or a methyl or ethyl group; Z represents a divalent linking hydrocarbyl group; m is 0 or 1; when m=0, Y.sup.1 represents O, NR.sup.3 or N.sup.+ R.sup.3 R.sup.4 X.sup.- and when m=1 Y.sup.1 represents O; Y.sup.2 represents O, NR.sup.3, N.sup.+ R.sup.3 R.sup.4 X.sup.-, (R.sup.3 NCH.sub.2 CH.sub.2).sub.t, or ?(R.sup.3 R.sup.4 N.sup.+ CH.sub.2 CH.sub.2)X.sup.- !.sub.t ; R.sup.3 and R.sup.4, independently, represent C.sub.1 -C.sub.

Abstract: A mixture of lipophilic and amphiphilic/hydrophilic film-forming polymers of the formula (I)R--(CO).sub.m Y.sup.1 --(CH.sub.2 CHR.sup.1 O).sub.n --?CONH--Z--NHCO(OCH.sub.2 CHR.sup.2).sub.n' --Y.sup.2 --(CH.sub.2 CHR.sup.2 O).sub.n" !.sub.p --CONH--Z--NHCO--(OCH.sub.2 CHR.sup.1).sub.n --Y.sup.1 (CO).sub.m R (I)where R represents (i) an alkyl, alkenyl or alkaryl group of from 1 to 30 carbon atoms or (ii) a polypropylene oxide group or polybutylene oxide group; R.sup.1 and R.sup.2, each, independently, represent a hydrogen atom, or a methyl or ethyl group; Z represents a divalent linking hydrocarbyl group; m is 0 or 1; when m=0, Y.sup.1 represents O, NR.sup.3 or N.sup.+ R.sup.3 R.sup.4 X.sup.- and when m=1 Y.sup.1 represents O; Y.sup.2 represents O, NR.sup.3, N.sup.+ R.sup.3 R.sup.4 X.sup.-, (R.sup.3 NCH.sub.2 CH.sub.2).sub.t, or ?(R.sup.3 R.sup.4 N.sup.+ CH.sub.2 CH.sub.2)X.sup.- !.sub.t ; R.sup.3 and R.sup.4, independently, represent C.sub.1 -C.sub.

Abstract: The combination of minoxidil and 2-n-nonyl-1,3-dioxolane is effective in promoting hair growth when applied once daily.

Abstract: New and improved method for the transdermal administration of agents is provided utilizing iontophoresis in conjunction with a water-insoluble, stratum corneum-lipid modifier. The lipid modifier may be used prior to iontophoresis or simultaneously therewith. The lipid modifier may be selected from a wide variety of moieties of the general formula R--X where R is a C.sub.5 to C.sub.28 alkyl or unsaturated alkyl and X is a member of the following: 1,3-dioxane; 1,3-dioxolane; lactam; morpholine; --COOH; --OH; --COOR'; --C--N(R').sub.2 ; cyclo ethylene and propylene carbonates; --CONH.sub.2 ; --(CH.sub.2 --CH.sub.2 O).sub.n H; ##STR1## acetals, and hemiacetals; and wherein R' is lower alkyl (e.g., C.sub.1 to C.sub.3) and n is an integer of from 1 to 20. Optionally there may be present a polar, water-soluble chemical compound from the group of alcohols, glycols, lactams, dioxolanes, esters, ureas, morpholine and the like. Compositions and articles useful in the processes of the present invention are also provided.

Abstract: Malignancy-induced hypercalcemia is treated with thionapthene-2-carboxylic acid (TNCA) and the pharmaceutically acceptable salts thereof. The treatment is also effective in tumor bearing hosts even before there is significant abnormal serum calcium levels. There is no "escape" from the hypocalcemic effects of these compounds as with e.g., calcitonin. The useful dosage in humans for TNCA itself ranges from about 1 to about 60 mg/kg/day preferably from about 2 to about 30 mg/kg/day and more preferably from about 5 to about 20 mg/kg/day (20 mg is approximately 0.106 mmol) Orally administered TNCA or salts thereof, is a much desired and obviously clinically advantageous mode of administering compounds to control or ameliorate hypercalcemia.

Abstract: A transdermal medication device for applying medication on the skin of the user comprising upper and lower layers having cooperating filaments for detachably securing the upper layer to the lower layer. The lower layer has an opening therethrough, the upper layer carrying a medication reservoir which seats in the opening. In one form of the invention, the device is a patch attached by pressure-sensitive adhesive to the skin. In another form of the invention, the lower layer is a band for attaching the device about the chest, waist, arm or leg of the user.